Overview
- An individual participant–level meta-analysis pooled 19 placebo-controlled trials with 123,940 participants and four intensity trials with 30,724 participants, with median follow-up of about 4–5 years.
- Of 66 non‑muscle, non‑diabetes outcomes drawn from product labels, only four showed a significant excess with statins—abnormal liver transaminases, other liver test abnormalities, minor urinary composition changes, and oedema—with absolute excess risks generally under 0.2% per year.
- Higher-intensity therapy showed a dose–response for liver enzyme elevations largely driven by an atorvastatin 80 mg trial, without increases in clinical liver disease such as hepatitis, liver failure, or jaundice.
- The trials found no causal link between statins and commonly cited problems including cognitive impairment or dementia, depression, sleep disturbance, acute kidney injury, peripheral neuropathy, sexual dysfunction, weight gain, fatigue, or headache.
- The authors and cardiovascular charities emphasize that benefits far outweigh harms—preventing hundreds to thousands of major vascular events over five years—while noting limited power for extremely rare adverse events and ongoing work to scrutinize liver biochemistry in more detail.